CN1544029A - Medicine for treating chronic kidney failure and its preparing process - Google Patents
Medicine for treating chronic kidney failure and its preparing process Download PDFInfo
- Publication number
- CN1544029A CN1544029A CNA2003101109342A CN200310110934A CN1544029A CN 1544029 A CN1544029 A CN 1544029A CN A2003101109342 A CNA2003101109342 A CN A2003101109342A CN 200310110934 A CN200310110934 A CN 200310110934A CN 1544029 A CN1544029 A CN 1544029A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- chronic kidney
- treatment
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 63
- 229940079593 drug Drugs 0.000 title claims description 25
- 238000000034 method Methods 0.000 title abstract description 9
- 208000020832 chronic kidney disease Diseases 0.000 title abstract description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 210000003734 kidney Anatomy 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 230000001684 chronic effect Effects 0.000 claims description 23
- 229920002472 Starch Polymers 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 20
- 241000180649 Panax notoginseng Species 0.000 claims description 15
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000000643 oven drying Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000282461 Canis lupus Species 0.000 abstract 1
- 241000758993 Equisetidae Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 230000005070 ripening Effects 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 46
- 229940109239 creatinine Drugs 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese preparation for treating chronic kidney failure and process for preparation, which is a prepared from Ligusticum wallichii, astragalus root, rhubarb horsetails, Chinese angelica root, epimeddium, dried rehmannia root, root of herbaceous peony, oriental water plantain rhizome, poria cocos wolf, pseudo-ginseng as raw material through disintegration, dissolvent extraction, ripening, sterilizing and granulation.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of chronic kidney hypofunction, is the Chinese patent medicine of feedstock production with Chinese medicine specifically, the invention still further relates to the preparation method of this medicine.
Background technology
Chronic kidney hypofunction is that various chronic renal diseases develop into to a certain degree, cause excretory function, homeostasis function and the endocrine function of kidney to be badly damaged, and one group of clinical syndrome group of corresponding clinical manifestation appears, and be one group of common frdquently encountered disease disease, annual morbidity is up to 1,00/,100,000.Though the medicine of treatment nephropathy is a lot of, its unsatisfactory curative effect.Therefore, carrying out property of the remaining nephron damage to a variety of causes caused causes chronic kidney hypofunction, still lacks the method for effectively preventing and treating.Searching can effectively delay the medicine or the method for carrying out property of remaining nephron damage speed, is the important subject in nephrology field.
Summary of the invention
The object of the present invention is to provide a kind ofly can effectively delay carrying out property of remaining nephron damage speed the medicine of treatment chronic kidney hypofunction.
Another object of the present invention provides the preparation method of this medicine.
Solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to the chronic kidney hypofunction pathogenic mechanism, with reference to the modern pharmacology achievement in research, from motherland medicine treasure-house, filter out with tonify Qi of the kidney for main and auxiliary with nourishing blood and promoting blood circulation, dry and rush down turbid natural plants Chinese medicine, by the theory of Chinese medical science prescription, reach the serum creatinine concentration that reduces the chronic kidney hypofunction patient, improve anemia, improving appetite, alleviate gastrointestinal symptom, delay residual kidney and damage speed, treatment chronic kidney hypofunction patient's purpose.
Medicine of the present invention is made by the following weight proportion raw material:
Rhizoma Chuanxiong 15-25 Radix Astragali 40-50 Radix Et Rhizoma Rhei 12-18 Radix Angelicae Sinensis 20-25 Herba Epimedii 15-20
Radix Rehmanniae 15-25 Radix Paeoniae Alba 10-15 Rhizoma Alismatis 15-20 Poria 15-20 Radix Notoginseng 6-8
The preferred weight ratio range of preparation medicine of the present invention is:
Rhizoma Chuanxiong 15-20 Radix Astragali 40-45 Radix Et Rhizoma Rhei 12-15 Radix Angelicae Sinensis 20-22 Herba Epimedii 15-18
Radix Rehmanniae 15-20 Radix Paeoniae Alba 12-15 Rhizoma Alismatis 15-18 Poria 15-18 Radix Notoginseng 6-7
The optimum weight proportioning of preparation medicine of the present invention is:
Rhizoma Chuanxiong 20 Radixs Astragali 40 Radix Et Rhizoma Rhei 15 Radix Angelicae Sinensis 20 Herba Epimedii 15
The Radix Rehmanniae 20 Radix Paeoniae Albas 15 Rhizoma Alismatis 15 Poria 15 Radix Notoginseng 6
Above-mentioned each component is made medicine production method of the present invention is:
Press described proportioning other raw material pulverizing except that Radix Notoginseng; More than extracting once with solvent refluxing; Merge extractive liquid, is concentrated into the thick paste shape, and adds the appropriate amount of starch mixing, and oven dry is collected dry extract and beaten powder; Add raw sangqi ginseng powder and appropriate amount of starch mixing more in proportion; Make binding agent with ethanol, granulate; Dry finished product.
The solvent that above-mentioned backflow is adopted is 50% ethanol; Reflux, extract, three times, each 1.5 hours; Above-mentioned be concentrated into the thick paste shape and add appropriate amount of starch be meant that adding weight ratio is 1～1.5% starch; The above-mentioned appropriate amount of starch that adds with Radix Notoginseng powder is meant that the weight of starch adding back patent medicine is 4～4.5% of crude drug in whole weight; Above-mentioned binding agent is 80% ethanol; Granulate: 16 mesh sieve grains; Oven drying at low temperature below 60 ℃ is adopted in oven dry.
During above-mentioned solvent refluxing extracted, solvent load satisfied following proportioning, and weight is in kilogram, and volume is in liter:
For the first time: the weight of crude drug: solvent volume=1: 2.5～3
For the second time: the weight of crude drug: solvent volume=1: 1.5～2
For the third time with for the second time.
Since medicine of the present invention be according to the traditional Chinese medical science monarch, minister, help, make principle to carry out prescription, promptly monarch drug selects the Radix Astragali, tonifies Qi of the kidney; Ministerial drug selects SIWU TANG (Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Radix Rehmanniae, the Radix Paeoniae Alba)+Herba Epimedii, and the kidney warming nourishes blood; Adjuvant drug selects Radix Notoginseng, nourishing blood and promoting blood circulation; Messenger drug selects Radix Et Rhizoma Rhei, Rhizoma Alismatis, Poria, and drying, it is turbid to rush down.Therefore, full side's function is: tonify Qi of the kidney, nourishing blood and promoting blood circulation, dry that it is turbid to rush down.
In order to understand the therapeutic effect of medicine of the present invention, in 600 rats, carried out zoopery with medicine of the present invention, find that this medicine can significantly improve the oxidation resistance of 5/6 nephrectomy chronic kidney hypofunction rat, promote outgrowth mesangial cell apoptosis, suppress residual renal fibrosis, reduce plasma creatinine and urea nitrogen concentration, haematochrome increasing, improve the general situation of experimental rat, reduce the mortality rate of experimental rat, prolong the life-span of experimental rat.Be used for the thousands of examples of clinical treatment chronic kidney hypofunction patient in new bridge hospital in 1996, its therapeutical effect is similar to the zoopery result, significantly is better than commercially available similar Chinese patent medicine preparation " NIAODUQING " granule of existing Ministry of Public Health certification.
The instructions of taking of medicine of the present invention: adult's chronic kidney hypofunction patient obeys each 1.35～2.25g every day 3 times.
For the beneficial effect of medicine of the present invention is described, part chronic kidney hypofunction patient takes medicine of the present invention and takes that " NIAODUQING " curative effect of medication tabulates 1 more as follows, table 2, is the independent sample analytic statistics result of SPSS10 statistical software (non-matching T-Test).
Table 1 medicine of the present invention compares (not dialysis patient) with " NIAODUQING " curative effect
Each organizes statistical data
| Group | The example number | Mean | Standard deviation | Standard error | |
| Age | Medicine group of the present invention | 48 | ?44.6042 | ?14.5511 | ?2.1003 |
| The NIAODUQING group | 35 | ?46.0571 | ?17.1823 | ?2.9043 | |
| Length of stay | Medicine group of the present invention | 48 | ?32.2500 | ?27.9593 | ?4.0356 |
| The NIAODUQING group | 35 | ?20.7714 | ?11.1437 | ?1.8836 | |
| Serum creatinine before the treatment | Medicine group of the present invention | 48 | ?419.1708 | ?169.5101 | ?24.4667 |
| The NIAODUQING group | 35 | ?429.3400 | ?169.9926 | ?28.7340 | |
| Treatment back serum creatinine | Medicine group of the present invention | 48 | ?369.7188 | ?162.3229 | ?23.4293 |
| The NIAODUQING group | 35 | ?445.4829 | ?197.1881 | ?33.3309 | |
| Treatment back creatinine value added | Medicine group of the present invention | 48 | -46.9063 | ?55.4587 | ?8.0048 |
| The NIAODUQING group | 35 | 13.2857 | ?71.8800 | ?12.1499 | |
| Treatment back creatinine moon value added | Medicine group of the present invention | 48 | -65.8162 | ?86.1770 | ?12.4386 |
| The NIAODUQING group | 35 | 7.1529 | ?126.9892 | ?21.4651 | |
| Treatment back creatinine moon increment rate | Medicine group of the present invention | 48 | -.1506 | .1735 | ?2.505E-02 |
| The NIAODUQING group | 35 | 4.162E-03 | .3103 | ?5.244E-02 |
Statistical analysis between table 2 group (independent sample analysis)
| Homogeneity of variance Levene ' s check | Mean differs significance test (t-check) | |||||||||
| The F value | Marginal value | The t value | Degree of freedom | P value (bilateral) | Inequality | Standard error | 95% value letter is interval | |||
| Low | High | |||||||||
| Age | Suppose to equate | .923 | .340 | -.416 | ?81 | .678 | -1.4530 | ?3.4917 | -8.4004 | ?5.4945 |
| Suppose not wait | -.405 | ?65.834 | .687 | -1.4530 | ?3.5842 | -8.6094 | ?5.7034 | |||
| Length of stay | Suppose to equate | 11.347 | .001 | 2.296 | ?81 | .024 | 11.4786 | ?4.9985 | ?1.5331 | ?21.4240 |
| Suppose not wait | 2.577 | ?65.418 | .012 | 11.4786 | ?4.4535 | ?2.5853 | ?20.3718 | |||
| Serum creatinine before the treatment | Suppose to equate | .700 | .405 | -.270 | ?81 | .788 | -10.1692 | ?37.7224 | -85.2249 | ?64.8865 |
| Suppose not wait | -.269 | ?73.301 | .788 | -10.1692 | ?37.7394 | -85.3784 | ?65.0401 | |||
| Treatment back serum creatinine | Suppose to equate | 3.898 | .052 | -1.917 | ?81 | .059 | -75.7641 | ?39.5182 | -154.3929 | ?2.8647 |
| Suppose not wait | -1.860 | ?64.507 | .067 | -75.7641 | ?40.7416 | -157.1425 | ?5.6143 | |||
| Treatment back creatinine value added | Suppose to equate | 1.092 | .299 | -4.307 | ?81 | .000 | -60.1920 | ?13.9756 | -87.9990 | -32.3849 |
| Suppose not wait | -4.137 | ?61.535 | .000 | -60.1920 | ?14.5498 | -89.2810 | -31.1029 | |||
| Treatment back creatinine moon value added | Suppose to equate | 2.826 | .097 | -3.119 | ?81 | .003 | -72.9692 | ?23.3948 | -119.5175 | -26.4208 |
| Suppose not wait | -2.941 | ?56.092 | .005 | -72.9692 | ?24.8086 | -122.6650 | -23.2733 | |||
| Treatment back creatinine moon increment rate | Suppose to equate | 6.467 | .013 | -2.893 | ?81 | .005 | -.1547 | ?5.347E-02 | -.2611 | -4.8330E-02 |
| Suppose not wait | -2.662 | ?49.418 | .010 | -.1547 | ?5.812E-02 | -.2715 | -3.7959E-02 | |||
Data declaration:
Before treatment back serum creatinine value added=treatment back-treatment
The treatment back serum creatinine moon value added=[(treatment back-treatment is preceding)/treat natural law/30 day]
Treatment back serum creatinine moon increment rate (the creatinine moon value added/the preceding serum creatinine of treatment)
Matched group " NIAODUQING " is the Chinese patent medicine preparation that the commercially available treatment chronic kidney hypofunction of Ministry of Public Health certification is arranged.
Fruit is analyzed: from above-mentioned statistical result as can be seen, index there was no significant differences such as the patient age of " of the present invention group " and " NIAODUQING " group, length of stay, the preceding serum creatinine concentration of treatment, two groups have comparability; Treatment back " of the present invention group " serum creatinine significantly descends, and " NIAODUQING " group serum creatinine does not only descend, and slightly rises on the contrary; " of the present invention group " treatment back creatinine moon value added, the creatinine moon, index such as increment rate significantly was better than " NIAODUQING " group.
Medicine of the present invention proves through zoopery and clinical experience, can reduce the chronic kidney hypofunction patient serum creatinine concentration, improve anemia, improving appetite, alleviate gastrointestinal symptom, delay residual kidney and damage speed, be applicable to treatment early, mid-term chronic kidney hypofunction and chronic nephritis patient.
The specific embodiment:
Embodiment 1: take by weighing raw material by following proportioning, weight is in kilogram:
Rhizoma Chuanxiong 25 Radixs Astragali 50 Radix Et Rhizoma Rhei 18.75 Radix Angelicae Sinensis 25 Herba Epimedii 18.75
The Radix Rehmanniae 25 Radix Paeoniae Albas 18.75 Rhizoma Alismatis 18.75 Poria 18.75 Radix Notoginseng 7.5
Above-mentioned other raw material pulverizing except that Radix Notoginseng; With 50% alcohol reflux 3 times, each 1.5 hours, ethanol consumption 600,000 ml for the first time, for the second time and for the third time each 400,000 ml of ethanol consumption; Merge extractive liquid, is concentrated into the thick paste shape, adds 3 kilograms of starch mixings, puts the dish oven dry, collects dry extract and beats powder; Add raw sangqi ginseng powder and appropriate amount of starch mixing again, described appropriate amount of starch is meant that starch adds the weight to 9 kilogram of back patent medicine; As binding agent, 16 mesh sieves are granulated with 80% ethanol; Oven drying at low temperature below 60 ℃; Behind the 14 mesh sieve granulate, with No. 0 capsule subpackage, every 0.45g, adorns about 400 bottles altogether by 50 every bottle.
Embodiment 2: the weight proportion of pressing embodiment 2 in the table 3 is other raw material pulverizing except that Radix Notoginseng; With 50% alcohol reflux 3 times, each 1.5 hours; The ethanol consumption satisfies following proportioning, and weight is in kilogram, and volume is in liter:
For the first time: the weight of crude drug: ethanol volume=1: 2.5～3
For the second time: the weight of crude drug: ethanol volume=1: 1.5～2
For the third time with for the second time.
Merge extractive liquid, is concentrated into the thick paste shape, and adds the starch mixing of 1～1.5% weight ratio, and oven dry is collected dry extract and beaten powder; Add raw sangqi ginseng powder and appropriate amount of starch mixing more in proportion, described appropriate amount of starch is meant that the weight of starch adding back patent medicine is 4～4.5% of crude drug in whole weight; Ethanol with 80% is as binding agent, and 16 mesh sieves are granulated; Oven drying at low temperature below 60 ℃; Behind the 14 mesh sieve granulate, be distributed into capsule by every 0.45g.
Embodiment 3: press the weight proportion prescription of embodiment 3 in the table 3, method for making is with embodiment 2.
Embodiment 4: press the weight proportion prescription of embodiment 4 in the table 3, method for making is with embodiment 2.
Embodiment 5: press the weight proportion prescription of embodiment 5 in the table 3, method for making is with embodiment 2.
Embodiment 6: press the weight proportion prescription of embodiment 6 in the table 3, method for making is with embodiment 2.
Embodiment 7: press the weight proportion prescription of embodiment 7 in the table 3, method for making is with embodiment 2.
Each Example formulations of table 3 is formed
| Material name | Embodiment 2 (weight proportion) | Embodiment 3 (weight proportion) | Embodiment 4 (weight proportion) | Embodiment 5 (weight proportion) | Embodiment 6 (weight proportion) | Embodiment 7 (weight proportion) |
| Rhizoma Chuanxiong | ??15?? | ????17 | ????20 | ????21 | ????22 | ????25 |
| The Radix Astragali | ??40?? | ????42 | ????44 | ????46 | ????48 | ????50 |
| Radix Et Rhizoma Rhei | ??12?? | ????13 | ????14 | ????15 | ????16 | ????18 |
| Radix Angelicae Sinensis | ??20?? | ????21 | ????22 | ????23 | ????24 | ????25 |
| Herba Epimedii | ??15?? | ????16 | ????17 | ????18 | ????19 | ????20 |
| The Radix Rehmanniae | ??15??? | ????17 | ????19 | ????20 | ????22 | ????25 |
| The Radix Paeoniae Alba | ??10??? | ????11 | ????12 | ????13 | ????14 | ????15 |
| Rhizoma Alismatis | ??15??? | ????16 | ????17 | ????18 | ????19 | ????20 |
| Poria | ??15 | ????16 | ????17 | ????18 | ????19 | ????20 |
| Radix Notoginseng | ??6 | ???6.2 | ????6.5?? | ????7 | ????7.5 | ????8 |
Claims (8)
1, a kind of medicine for the treatment of chronic kidney hypofunction is characterized in that: it is the medicament of being made by the following weight proportion raw material
Rhizoma Chuanxiong 15-25 Radix Astragali 40-50 Radix Et Rhizoma Rhei 12-18 Radix Angelicae Sinensis 20-25 Herba Epimedii 15-20
Radix Rehmanniae 15-25 Radix Paeoniae Alba 10-15 Rhizoma Alismatis 15-20 Poria 15-20 Radix Notoginseng 6-8
2, a kind of medicine for the treatment of chronic kidney hypofunction according to claim 1, wherein the weight proportion of each raw material is
Rhizoma Chuanxiong 15-20 Radix Astragali 40-45 Radix Et Rhizoma Rhei 12-15 Radix Angelicae Sinensis 20-22 Herba Epimedii 15-18
Radix Rehmanniae 15-20 Radix Paeoniae Alba 12-15 Rhizoma Alismatis 15-18 Poria 15-18 Radix Notoginseng 6-7
3, a kind of medicine for the treatment of chronic kidney hypofunction according to claim 1, wherein the weight proportion of each raw material is
Rhizoma Chuanxiong 20 Radixs Astragali 40 Radix Et Rhizoma Rhei 15 Radix Angelicae Sinensis 20 Herba Epimedii 15
The Radix Rehmanniae 20 Radix Paeoniae Albas 15 Rhizoma Alismatis 15 Poria 15 Radix Notoginseng 6
4, according to claim 1,2 or 3 described a kind of medicines for the treatment of chronic kidney hypofunction, it is characterized in that: said medicament is a said dosage form on any pharmaceutics.
5, a kind of medicine for the treatment of chronic kidney hypofunction according to claim 4, it is characterized in that: said medicament is a capsule.
6, according to claim 1,2 or 3 described a kind of preparation methoies for the treatment of the medicine of chronic kidney hypofunction, it is characterized in that: press described proportioning other raw material pulverizing except that Radix Notoginseng; More than extracting once with solvent refluxing; Merge extractive liquid, is concentrated into the thick paste shape, and adds the appropriate amount of starch mixing, and oven dry is collected dry extract and beaten powder; Add raw sangqi ginseng powder and appropriate amount of starch mixing more in proportion; Make binding agent with ethanol, granulate; Dry finished product.
7, a kind of preparation method for the treatment of the medicine of chronic kidney hypofunction according to claim 6 is characterized in that: the solvent that described backflow is adopted is 50% ethanol; Described reflux, extract, three times, each 1.5 hours; Described be concentrated into the thick paste shape and add appropriate amount of starch be meant that adding weight ratio is 1 ~ 1.5% starch; The described appropriate amount of starch that adds with Radix Notoginseng powder is meant that the weight of starch adding back patent medicine is 4～4.5% of crude drug in whole weight; Described binding agent is 80% ethanol; Granulate: 16 mesh sieve grains; Oven drying at low temperature below 60 ℃ is adopted in oven dry.
8, a kind of preparation method for the treatment of the medicine of chronic kidney hypofunction according to claim 7 is characterized in that: during described solvent refluxing extracted, solvent load satisfied following proportioning, and weight is in kilogram, and volume is in liter:
For the first time: the weight of crude drug: solvent volume=1: 2.5～3
For the second time: the weight of crude drug: solvent volume=1: 1.5～2
For the third time with for the second time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310110934 CN1275630C (en) | 2003-11-11 | 2003-11-11 | Medicine for treating chronic kidney failure and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310110934 CN1275630C (en) | 2003-11-11 | 2003-11-11 | Medicine for treating chronic kidney failure and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1544029A true CN1544029A (en) | 2004-11-10 |
| CN1275630C CN1275630C (en) | 2006-09-20 |
Family
ID=34335826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310110934 Expired - Lifetime CN1275630C (en) | 2003-11-11 | 2003-11-11 | Medicine for treating chronic kidney failure and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1275630C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360156C (en) * | 2005-12-13 | 2008-01-09 | 丽珠医药集团股份有限公司 | Chinese medicine composition new use |
| CN101028421B (en) * | 2007-04-16 | 2010-05-19 | 北京艺信堂医药研究所 | Chinese medicine for treating chronic kidney failure |
| CN101161262B (en) * | 2006-10-12 | 2012-05-30 | 江西省药物研究所 | A medicine for treating chronic renal failure and its preparing method |
| CN102818861A (en) * | 2012-05-10 | 2012-12-12 | 丽珠医药集团股份有限公司 | Quality control method and application of Qingdu Anshen capsule |
| CN103301355A (en) * | 2013-07-01 | 2013-09-18 | 郝伟英 | Preparation method of chronic renal failure colon dialysate |
| CN103330868A (en) * | 2013-07-01 | 2013-10-02 | 郝伟英 | Intestinal tract replenishing liquid for chronic renal failure |
| CN103349130A (en) * | 2013-07-22 | 2013-10-16 | 北京绿源求证科技发展有限责任公司 | Food health preserving tea electuary for nourishing kidney |
| CN103424498A (en) * | 2012-05-25 | 2013-12-04 | 丽珠集团利民制药厂 | Establishing method and application of fingerprint of detoxifying and kidney harmonizing capsule |
-
2003
- 2003-11-11 CN CN 200310110934 patent/CN1275630C/en not_active Expired - Lifetime
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360156C (en) * | 2005-12-13 | 2008-01-09 | 丽珠医药集团股份有限公司 | Chinese medicine composition new use |
| CN101161262B (en) * | 2006-10-12 | 2012-05-30 | 江西省药物研究所 | A medicine for treating chronic renal failure and its preparing method |
| CN101028421B (en) * | 2007-04-16 | 2010-05-19 | 北京艺信堂医药研究所 | Chinese medicine for treating chronic kidney failure |
| CN102818861A (en) * | 2012-05-10 | 2012-12-12 | 丽珠医药集团股份有限公司 | Quality control method and application of Qingdu Anshen capsule |
| CN103424498A (en) * | 2012-05-25 | 2013-12-04 | 丽珠集团利民制药厂 | Establishing method and application of fingerprint of detoxifying and kidney harmonizing capsule |
| CN103424498B (en) * | 2012-05-25 | 2015-05-06 | 丽珠集团利民制药厂 | Establishing method and application of fingerprint of detoxifying and kidney harmonizing capsule |
| CN103301355A (en) * | 2013-07-01 | 2013-09-18 | 郝伟英 | Preparation method of chronic renal failure colon dialysate |
| CN103330868A (en) * | 2013-07-01 | 2013-10-02 | 郝伟英 | Intestinal tract replenishing liquid for chronic renal failure |
| CN103330868B (en) * | 2013-07-01 | 2015-03-11 | 郝伟英 | Intestinal tract replenishing liquid for chronic renal failure |
| CN103349130A (en) * | 2013-07-22 | 2013-10-16 | 北京绿源求证科技发展有限责任公司 | Food health preserving tea electuary for nourishing kidney |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1275630C (en) | 2006-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1785284A (en) | Medicinal composition containing flowery knotwood root | |
| CN1275630C (en) | Medicine for treating chronic kidney failure and its preparing process | |
| CN1709469A (en) | Ginseng-astragalus dispersion tablet formulation, and its preparing process | |
| CN1256133C (en) | Antifatigue Chinese medicine composition and its prepn process | |
| CN1771977A (en) | Notoginseng glycol-saponin composition and its prepn and use | |
| CN1943737A (en) | A Chinese traditional medicinal composition used for treatment of nephritis and its preparation method | |
| CN1182858C (en) | Heart-nourishing tea capsule and its prepn | |
| CN1611232A (en) | Medicinal composition with main effect of antifatigue, radioresistance and melancholia-resistance and its preparing method | |
| CN1943621A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN109172637B (en) | Preparation method of capsule for treating rheumatism | |
| CN1199679C (en) | Medicine for nourishing yin and fortifying kidney, benefiting qi and fortifying spleen , and its preparation method | |
| CN1210054C (en) | Novel preparation method for ageratum zhengqi capsule | |
| CN1943718A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN1733206A (en) | Chinese traditional medicine preparation for curing mastoplasia | |
| CN116920061B (en) | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof | |
| CN103301414B (en) | Gout, short kidney are arranged, repair kidney damages pharmaceutical composition and its preparation method and application | |
| CN1814049A (en) | Compound Chinese medicine for treating chronic liver disease and preparation | |
| CN1282480C (en) | Head ache capsule preparation | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn | |
| CN1144123A (en) | Xinmaitai prescription and producing process thereof | |
| CN101049463A (en) | Preparation of Chinese traditional medicine in use for hepatic disease and preparation method | |
| CN1911300A (en) | Compound traditional Chinese medicine prepn. for treating chronic reactivation hepatitis B and its prepn. method | |
| CN1173728C (en) | Medicine for delaying senility and its preparing process | |
| CN1049834C (en) | Medicine for curing hepatitis and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NATIONAL TRADITIONAL CHINESE MEDICINE MODERNIZATI Free format text: FORMER OWNER: YUAN FAHUAN Effective date: 20050826 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050826 Address after: 519000, Zhuhai Osmanthus Road North Franc group scientific research building two floor Applicant after: NATIONAL ENGINEERING RESEARCH CENTER FOR MODERNIZATION OF TRADITIONAL CHINESE MEDICINE Address before: 400037 Xinqiao Hospital, Xinqiao Hospital, Xinqiao Hospital, Shapingba District, Chongqing, Applicant before: Yuan Fahuan |
|
| ASS | Succession or assignment of patent right |
Owner name: NATIONAL TRADITIONAL CHINESE MEDICINE MODERNIZATI Free format text: FORMER OWNER: YUAN FAHUAN Owner name: ZHUHAI MODERN MEDICINE HIGH TECHNOLOGY CO.,LTD. Effective date: 20050909 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050909 Address after: 519000, Zhuhai Osmanthus Road North Franc group scientific research building two floor Applicant after: NATIONAL ENGINEERING RESEARCH CENTER FOR MODERNIZATION OF TRADITIONAL CHINESE MEDICINE Co-applicant after: ZHUHAI XIANDAI TRADITIONAL CHINESE MEDICINE HIGH-TECH Co.,Ltd. Address before: 400037 Xinqiao Hospital, Xinqiao street, Shapingba District, Chongqing Applicant before: Yuan Fahuan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LIVZON PHARMACEUTICAL Group Inc. Assignor: NATIONAL ENGINEERING RESEARCH CENTER FOR MODERNIZATION OF TRADITIONAL CHINESE MEDICINE|ZHUHAI XIANDAI TRADITIONAL CHINESE MEDICINE HIGH-TECH Co.,Ltd. Contract fulfillment period: 2008.7.31 to 2018.7.31 Contract record no.: 2008990000368 Denomination of invention: Medicine for treating chronic kidney failure and its preparing process Granted publication date: 20060920 License type: Exclusive license Record date: 20080905 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.7.31 TO 2018.7.31 Name of requester: LIZHU MEDICINE GROUP CO., LTD. Effective date: 20080905 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060920 |
|
| CX01 | Expiry of patent term |